Gelteq (GELS) Registration filing summary

Company overview and business model

• Develops and commercializes white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products, focusing on out-licensing technology and manufacturing under license.

• Product suite spans five core verticals: pets, sports, pharmaceutical, over-the-counter, and nutraceutical, leveraging patent-pending multiple-ingredient dosage forms.

• Business model centers on licensing, partnerships, and white/private label manufacturing, with a focus on rapid commercialization and market entry through established partners.

• Holds granted and pending patents in multiple jurisdictions for gel-based delivery systems and has ongoing R&D collaborations with leading academic institutions.

Financial performance and metrics

• For the year ended June 30, 2023: revenue from contracts with customers was AUD $79,843 (USD $57,487), down from AUD $147,536 (USD $106,226) in 2022, reflecting a focus on research.

• Net loss for the year ended June 30, 2023 was AUD $3,506,220, compared to a net loss of AUD $3,368,891 in 2022; for the nine months ended March 31, 2024, net loss was AUD $2,413,063.

• As of March 31, 2024, cash and cash equivalents were AUD $145,861, with current liabilities exceeding current assets by AUD $2,987,496, raising substantial doubt about going concern.

• Intangible assets (mainly trade secrets and patents) comprise over 96% of total assets, with no impairment recognized as of March 31, 2024.

• Deferred revenue as of March 31, 2024 was AUD $125,359, reflecting prepayments for undelivered orders.

Use of proceeds and capital allocation

• Net proceeds of approximately USD $5.38 million from the IPO are allocated to IP protection, R&D, regulatory and compliance, sales and marketing, manufacturing equipment, and working capital.

• Capital will also support expansion of manufacturing capacity, including a dedicated production line with a GMP-certified manufacturer.

• Management retains broad discretion over allocation, with potential for opportunistic acquisitions or investments.